UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended July 4, 2010
OR
TRANSITION REPORT PURSUANT TO SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _______ to _______
COMMISSION FILE NUMBER 1-3619
____
PFIZER INC.
(Exact name of registrant as specified in its charter)
DELAWARE
(State of Incorporation)
13-5315170
(I.R.S. Employer Identification No.)
235 East 42nd Street, New York, New York 10017
(Address of principal executive offices) (zip code)
(212) 733-2323
(Registrant s telephone number)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.
YES x NO o
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T ( 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
YES x NO o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act (check one):
Large Accelerated filer x
Accelerated filer o
Non-accelerated filer o
Smaller reporting company o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
YES o NO x
At August 9, 2010, 8,038,278,387 shares of the issuer s voting common stock were outstanding.
FORM 10-Q
For the Quarter Ended
July 4, 2010
Table of Contents
PART I. FINANCIAL INFORMATION
Page
Item 1.
Financial Statements
Condensed Consolidated Statements of Income for the three and six months ended July 4, 2010, and June 28, 2009
Condensed Consolidated Balance Sheets as of July 4, 2010, and December 31, 2009
Condensed Consolidated Statements of Cash Flows for the six months ended July 4, 2010, and June 28, 2009
Notes to Condensed Consolidated Financial Statements
Review Report of Independent Registered Public Accounting Firm
22
Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
23
Item 3.
Quantitative and Qualitative Disclosures About Market Risk
54
Item 4.
Controls and Procedures
54
PART II. OTHER INFORMATION
Item 1.
Legal Proceedings
55
Item 1A.
Risk Factors
59
Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds
59
Item 3.
Defaults Upon Senior Securities
59
Item 5.
Other Information
59
Item 6.
Exhibits
59
Signature
60
PART I - FINANCIAL INFORMATION
Item 1. Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(UNAUDITED)
Three Months Ended
Six Months Ended
(MILLIONS, EXCEPT PER COMMON SHARE DATA)
July 4,
2010
June 28,
2009
July 4,
2010
June 28,
2009
Revenues
17,327
10,984
34,077
21,851
Costs and expenses:
Cost of sales(a)
3,795
1,756
8,101
3,164
Selling, informational and administrative expenses(a)
4,807
3,350
9,243
6,226
Research and development expenses(a)
2,187
1,695
4,413
3,400
Amortization of intangible assets
1,407
583
2,816
1,161
Acquisition-related in-process research and development charges
20
74
20
Restructuring charges and certain acquisition-related costs
886
459
1,592
1,013
Other deductions net
271
72
685
15
Income from continuing operations before provision for taxes on income
3,974
3,049
7,153
6,852
Provision for taxes on income
1,488
786
2,634
1,860
Income from continuing operations
2,486
2,263
4,519
4,992
Discontinued operations net of tax
(1
Net income before allocation to noncontrolling interests
2,485
2,266
4,520
4,996
Less: Net income attributable to noncontrolling interests
10
19
Net income attributable to Pfizer Inc.
2,475
2,261
4,501
4,990
Earnings per share basic:
Income from continuing operations attributable to Pfizer Inc.
common shareholders
0.31
0.34
0.56
0.74
Discontinued operations net of tax
Net income attributable to Pfizer Inc. common shareholders
0.31
0.34
0.56
0.74
Earnings per share diluted:
Income from continuing operations attributable to Pfizer Inc.
common shareholders
0.31
0.34
0.56
0.74
Discontinued operations net of tax
Net income attributable to Pfizer Inc. common shareholders
0.31
0.34
0.56
0.74
Weighted-average shares used to calculate earnings per common share:
Basic
8,046
6,728
8,053
6,726
Diluted
8,072
6,752
8,085
6,752
Cash dividends paid per common share
0.18
0.16
0.36
0.48
(a)
Exclusive of amortization of intangible assets, except as disclosed inNote 9B. Goodwill and Other Intangible Assets: Other Intangible Assets.
See accompanying Notes to Condensed Consolidated Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(UNAUDITED)
(millions of dollars)
July 4,
2010*
Dec. 31,
2009**
Assets
Cash and cash equivalents
1,877
1,978
Short-term investments
17,391
23,991
Accounts receivable, less allowance for doubtful accounts
14,012
14,645
Short-term loans
515
1,195
Inventories
9,511
12,403
Current deferred tax assets and other current assets
7,113
6,962
Assets held for sale
682
496
Total current assets
51,101
61,670
Long-term investments and loans
10,524
13,122
Property, plant and equipment, less accumulated depreciation
20,041
22,780
Goodwill
43,142
42,376
Identifiable intangible assets, less accumulated amortization
62,231
68,015
Noncurrent deferred tax assets and other noncurrent assets
4,032
4,986
Total assets
191,071
212,949
Liabilities and Shareholders Equity
Short-term borrowings, including current portion of long-term debt
5,509
5,469
Accounts payable
3,078
4,370
Dividends payable
1,450
1,454
Income taxes payable
727
10,107
Accrued compensation and related items
1,789
2,242
Current deferred tax liabilities and other current liabilities
12,128
13,583
Total current liabilities
24,681
37,225
Long-term debt
37,765
43,193
Pension benefit obligations
5,969
6,392
Postretirement benefit obligations
3,246
3,243
Noncurrent deferred tax liabilities
17,344
17,839
Other taxes payable
9,538
9,000
Other noncurrent liabilities
5,650
5,611
Total liabilities
104,193
122,503
Preferred stock
56
61
Common stock
443
443
Additional paid-in capital
70,568
70,497
Employee benefit trusts
(25
(333
Treasury stock
(22,206
(21,632
Retained earnings
42,010
40,426
Accumulated other comprehensive (loss)/income
(4,407
552
Total Pfizer Inc. shareholders equity
86,439
90,014
Equity attributable to noncontrolling interests
439
432
Total shareholders equity
86,878
90,446
Total liabilities and shareholders equity
191,071
212,949
Unaudited.
**
Condensed from audited financial statements.
See accompanying Notes to Condensed Consolidated Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
Six Months Ended
(millions of dollars)
July 4,
2010
June 28,
2009
Operating Activities:
Net income before allocation to noncontrolling interests
4,520
4,996
Adjustments to reconcile net income before allocation to noncontrolling interests to net
cash (used in)/provided by operating activities:
Depreciation and amortization
4,264
2,014
Share-based compensation expense
243
169
Asset write-offs and impairment charges
833
270
Acquisition-related in-process research and development charges
74
20
Deferred taxes from continuing operations
1,610
731
Other non-cash adjustments
(92
(292
Changes in assets and liabilities, net of acquisitions and divestitures
(12,939
(247
Net cash (used in)/provided by operating activities
(1,487
7,661
Investing Activities:
Purchases of property, plant and equipment
(678
(522
Purchases of short-term investments
(3,531
(38,900
Proceeds from redemptions and sales of short-term investments
11,048
14,251
Purchases of long-term investments
(1,481
(5,266
Proceeds from redemptions and sales of long-term investments
3,156
3,484
Other investing activities
519
346
Net cash provided by/(used in) investing activities
9,033
(26,607
Financing Activities:
Increase in short-term borrowings
3,169
21,754
Principal payments on short-term borrowings
(7,321
(22,493
Proceeds from issuances of long-term debt
23,996
Principal payments on long-term debt
(2
(908
Purchases of common stock
(500
Cash dividends paid
(2,995
(3,200
Other financing activities
77
(106
Net cash (used in)/provided by financing activities
(7,572
19,043
Effect of exchange-rate changes on cash and cash equivalents
(75
25
Net (decrease)/increase in cash and cash equivalents
(101
122
Cash and cash equivalents at beginning of period
1,978
2,122
Cash and cash equivalents at end of period
1,877
2,244
Supplemental Cash Flow Information:
Cash paid during the period for:
Income taxes
11,311
1,109
Interest
1,342
299
See accompanying Notes to Condensed Consolidated Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Note 1. Basis of Presentation
We prepared the condensed consolidated financial statements following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by accounting principles generally accepted in the United States of America (U.S. GAAP) can be condensed or omitted. Balance sheet amounts and operating results for subsidiaries operating outside the U.S. are as of and for the three-month and six-month periods ended May 30, 2010, and May 24, 2009.
On October 15, 2009, we completed our acquisition of Wyeth and, commencing from the acquisition date, our financial statements include the assets, liabilities, operating results and cash flows of Wyeth. As a result, legacy Wyeth operations are reflected in our results of operations for the second-quarter and six-month 2010 periods, but not for the second-quarter and six-month 2009 periods. Also, legacy Wyeth cash flows are reflected for the six-month period in 2010, but not for the six-month period in 2009.
Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.
We are responsible for the unaudited financial statements included in this document. The financial statements include all normal and recurring adjustments that are considered necessary for the fair presentation of our financial position and operating results.
The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2009.
Note 2. Adoption of New Accounting Policies
The provisions of the following new accounting standards were adopted as of January 1, 2010 and did not have a significant impact on our consolidated financial statements:
An amendment to the recognition and measurement guidance for the transfers of financial assets.
An amendment to the guidelines for determining the primary beneficiary in a variable interest entity.
Note 3. Acquisition of Wyeth
On October 15, 2009 (the acquisition date), we acquired all of the outstanding equity of Wyeth in a cash-and-stock transaction, valued at the acquisition date at approximately $68 billion. While Wyeth now is a wholly owned subsidiary of Pfizer, the merger of local Pfizer and Wyeth entities may be pending or delayed in various international jurisdictions and integration in these jurisdictions is subject to completion of various local legal and regulatory obligations.
Recording of Assets Acquired and Liabilities Assumed
The following table summarizes the provisional amounts recognized for assets acquired and liabilities assumed as of the acquisition date, as well as adjustments made in the first six months of 2010 to the amounts initially recorded in 2009 (measurement period adjustments). The measurement period adjustments did not have a significant impact on our consolidated statements of income, balance sheets or cash flows in any period and, therefore, we have not retrospectively adjusted our financial statements. Certain estimated values are not yet finalized (see below) and are subject to change, which could be significant. We will finalize the amounts recognized as we obtain the information necessary to complete the analyses, but no later than one year from the acquisition date.
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
(millions of dollars)
Amounts Recognized
as of Acquisition
Date(a)
Measurement
Period
Adjustments
Amounts Recognized
as of Acquisition Date
(as adjusted)
Working capital, excluding inventories
16,342
73
16,415
Inventories
8,388
(172
8,216
Property, plant and equipment
10,054
(198
9,856
Identifiable intangible assets, excluding
in-process research and development(b)
37,595
(517
37,078
In-process research and development(b)
14,918
(875
14,043
Other noncurrent assets
2,394
2,394
Long-term debt
(11,187
(11,187
Benefit obligations
(3,211
36
(3,175
Net tax accounts(c)
(24,773
(105
(24,878
Other noncurrent liabilities
(1,908
(75
(1,983
Total identifiable net assets
48,612
(1,833
46,779
Goodwill(d)
19,954
1,833
21,787
Net assets acquired
68,566
68,566
Less: Amounts attributable to
noncontrolling interests
(330
(330
Total consideration transferred
68,236
68,236
(a)
As previously reported in Pfizer s 2009 Annual Report on Form 10-K.
(b)
The measurement period adjustments for Identifiable intangible assets primarily consist of adjustments recorded to reflect changes in the estimated fair value of certain acquired intangibles, principally in-process research and development assets. These adjustments were made largely to better reflect market participant assumptions about facts and circumstances existing as of the acquisition date. The measurement period adjustments did not result from intervening events subsequent to the acquisition date.
(c)
The measurement period adjustments for Net tax accounts primarily reflect the tax impact of the pre-tax measurement period adjustments offset by adjustments to uncertain tax positions following receipt of additional information from taxing authorities about facts and circumstances existing as of the acquisition date. The measurement period adjustments did not result from intervening events subsequent to the acquisition date.
(d)
Goodwill recognized as of the acquisition date (as adjusted) totaled $18,670 million for our Biopharmaceutical segment and $3,117 million for our Diversified segment. These amounts are not yet finalized and are subject to change.
The recorded amounts are provisional and subject to change. Specifically, the following items are subject to change:
Amounts for intangibles and inventory, pending finalization of valuation efforts.
Amounts for legal contingencies, pending the finalization of our examination and evaluation of the portfolio of filed cases.
Amounts for income tax assets, receivables and liabilities pending the filing of Wyeth pre-acquisition tax returns, including all required disclosures and documentation, as well as the receipt of information from taxing authorities, which may change certain estimates and assumptions used.
The allocation of goodwill among reporting units.
Note 4. Cost-Reduction Initiatives and Acquisition-Related Costs
We have incurred significant costs in connection with our cost-reduction initiatives (several programs initiated since 2005) and our acquisition of Wyeth on October 15, 2009.
Since the acquisition of Wyeth, our cost-reduction initiatives that were announced on January 26, 2009, but not completed as of December 31, 2009, have been incorporated into a comprehensive plan to integrate Wyeth s operations, generate cost savings and capture synergies across the combined company. We are focusing our efforts on achieving an appropriate cost structure for the combined company.
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
We incurred the following costs in connection with all of our cost-reduction initiatives and the acquisition of Wyeth:
Three Months Ended
Six Months Ended
(millions of dollars)
July 4,
2010
June 28,
2009
July 4,
2010
June 28,
2009
Transaction costs(a)
184
13
553
Integration costs(b)
211
101
419
129
Restructuring charges(c)
671
174
1,160
331
Restructuring charges and certain acquisition-related costs
886
459
1,592
1,013
Additional depreciation asset restructuring(d)
215
61
308
151
Implementation costs(e)
95
179
Total
1,101
615
1,900
1,343
(a)
Transaction costs represent external costs directly related to our acquisition of Wyeth and primarily include expenditures for banking, legal, accounting and other similar services. Substantially all of the costs incurred in the second quarter and first six months of 2009 were fees related to a $22.5 billion bridge term loan credit agreement entered into with certain financial institutions on March 12, 2009 to partially fund our acquisition of Wyeth. The bridge term loan credit agreement was terminated in June 2009 as a result of our issuance of approximately $24.0 billion of senior unsecured notes in the first half of 2009.
(b)
Integration costs represent external, incremental costs directly related to integrating Wyeth and primarily include expenditures for consulting and systems integration.
(c)
Restructuring charges include the following:
Costs Incurred
Three Months Ended
Six Months Ended
Activity
Accrual
(millions of dollars)
July 4,
2010
June 28,
2009
July 4,
2010
June 28,
2009
2005-2010
Through
July 4,
2010(1)
As of
July 4,
2010(2)
Employee termination costs
118
29
576
164
8,297
6,000
2,297
Asset impairments
497
73
503
91
1,955
1,955
Other
56
72
81
76
791
657
134
Total restructuring charges
671
174
1,160
331
11,043
8,612
2,431
(1)
Includes adjustments for foreign currency translation.
(2)
Included in Current deferred tax liabilities and other current liabilities ($1.6 billion) and Other noncurrent liabilities ($831 million).
Restructuring charges in 2010 are related to the integration of Wyeth. From the beginning of our cost-reduction initiatives in 2005 through July 4, 2010, Employee termination costs represent the expected reduction of the workforce by approximately 47,400 employees, mainly in manufacturing, sales and research, of which approximately 29,100 employees have been terminated as of July 4, 2010. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, pension and postretirement benefits, many of which may be paid out during periods after termination. Asset impairments primarily include charges to write down property, plant and equipment to fair value. Other primarily includes costs to exit certain assets and activities.
(d)
Additional depreciation asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions and are included in our condensed consolidated statements of income as follows:
Three Months Ended
Six Months Ended
(millions of dollars)
July 4,
2010
June 28,
2009
July 4,
2010
June 28,
2009
Cost of sales
113
32
126
95
Selling, informational and administrative expenses
102
162
14
Research and development expenses
21
20
42
Total
215
61
308
151
(e)
Implementation costs in the three months and six months ended June 28, 2009 represent external, incremental costs directly related to implementing cost-reduction initiatives prior to our acquisition of Wyeth, and primarily include expenditures related to system and process standardization and the expansion of shared services. For the three months ended June 28, 2009, implementation costs are included in Cost of sales ($13 million), Selling, informational and administrative expenses ($77 million), Research and development expenses ($11 million) and Other deductions net ($6 million income). For the six months ended June 28, 2009, implementation costs are included in Cost of sales ($26 million), Selling, informational and administrative expenses ($117 million), Research and development expenses ($31 million) and Other deductions net ($5 million).
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Note 5. Taxes on Income
Our effective tax rate for continuing operations was 37.4% for the second quarter of 2010, compared to 25.8% for the second quarter of 2009, and 36.8% for the first six months of 2010, compared to 27.1% for the first six months of 2009. The higher tax rates in the second quarter and first six months of 2010 are primarily the result of:
higher charges, incurred as a result of our acquisition of Wyeth, and the mix of jurisdictions in which those charges were incurred, and
the expiration of the U.S. research and development tax credit.
The effective tax rate for the first six months of 2010 was additionally impacted by the write-off of the deferred tax asset of approximately $270 million related to the Medicare Part D subsidy for retiree prescription drug coverage, resulting from changes in the U.S. healthcare legislation enacted in March 2010 concerning the tax treatment of that subsidy effective for tax years beginning after December 31, 2012, partially offset by $410 million in tax benefits for the resolution of certain tax positions pertaining to prior years with various foreign tax authorities.